These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1361777)
1. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD. Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777 [TBL] [Abstract][Full Text] [Related]
2. Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis. Gündüz Z; Kisaarslan FA; Düsünsel R; Poyrazoglu HM; Saraymen R; Per H Adv Perit Dial; 1999; 15():278-82. PubMed ID: 10682118 [TBL] [Abstract][Full Text] [Related]
3. Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1. Diamond MP; Kruger M; Saed GM Fertil Steril; 2004 Jun; 81(6):1657-64. PubMed ID: 15193491 [TBL] [Abstract][Full Text] [Related]
4. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147 [TBL] [Abstract][Full Text] [Related]
5. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis]. Matsuura R; Soma M; Maeda Y; Kasakura S Rinsho Byori; 1995 Dec; 43(12):1256-60. PubMed ID: 8569037 [TBL] [Abstract][Full Text] [Related]
6. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924 [TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related]
9. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease. Philips M; Juul AG; Selmer J; Lind B; Thorsen S Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392 [TBL] [Abstract][Full Text] [Related]
10. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC]. Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036 [TBL] [Abstract][Full Text] [Related]
11. Time to reconsider saline as the ideal rinsing solution during abdominal surgery. Połubinska A; Winckiewicz M; Staniszewski R; Breborowicz A; Oreopoulos DG Am J Surg; 2006 Sep; 192(3):281-5. PubMed ID: 16920418 [TBL] [Abstract][Full Text] [Related]
12. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250 [TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 and peritoneal transport in peritoneal dialysis patients. Wadhwa NK; Lin JJ; Parton L; Bereket G; Cabralda T; Suh H Adv Perit Dial; 1996; 12():33-8. PubMed ID: 8865868 [TBL] [Abstract][Full Text] [Related]
14. [Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure]. Piatkowska M; Kotschy M; Nartowicz E; Rajewski W Pol Merkur Lekarski; 1997 Jan; 2(9):205-7. PubMed ID: 10907030 [TBL] [Abstract][Full Text] [Related]
15. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity]. Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860 [TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients. Lin JJ; Parton L; Bereket G; Wadhwa NK Clin Nephrol; 1995 Nov; 44(5):310-5. PubMed ID: 8605711 [TBL] [Abstract][Full Text] [Related]
17. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1. Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the pro-thrombotic state in CAPD patients. Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409 [TBL] [Abstract][Full Text] [Related]
19. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462 [TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon. Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]